A study to evaluate the safety and tolerability of JNJ-70035108 and to evaluate how long JNJ-70035108 stays in and acts on the body (pharmacokinetics) when given as single and repeated doses to healthy participants
Latest Information Update: 06 Aug 2026
At a glance
- Drugs JNJ 70035108 (Primary)
- Indications Inflammation
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Janssen-Cilag
Most Recent Events
- 12 Sep 2025 New trial record